Geranylgeraniol

Research use only, not for human use.

Geranylgeraniol is an isoprenoid found in fruits, vegetables, and grains, including rice. Geranylgeraniol inhibits growth and induces apoptosis of various tumor cells. Geranylgeraniol protects monocytes against statin-induced cytotoxicity and suppresses the growth of Mycobacterium.

Geranylgeraniol is an isoprenoid found in fruits, vegetables, and grains, including rice. Geranylgeraniol inhibits growth and induces apoptosis of various tumor cells. Geranylgeraniol protects monocytes against statin-induced cytotoxicity and suppresses the growth of Mycobacterium.

Geranylgeraniol (0-10 μM; 24 h) dose-dependently suppresses the LPS-induced increase in the mRNA levels of Il-1β, Tnf-α, Il-6, and Cox-2.Geranylgeraniol (10 μM; 24 h) inhibits the phosphorylation of TAK1, IKKα/β, and NF-κB p65 proteins as well as NF-κB nuclear translocation induced by LPS while maintaining IκBα expression.Geranylgeraniol, (50 μM; 24 h) eliminates cell damage caused by Simvastatin (HY-17502) (10 μM) and Mevalonat (10 mM), and reduces the inflammatory marker and the damage of the mitochondria, maintaining its shape and component. Western Blot Analysis Cell Line:MG6 cell Concentration:0, 1, 10 μM Incubation Time:24 hours Result:Suppressed by TAK1, IKKα/β, and NF-κB p65 proteins level at 10 μM.RT-PCR Cell Line:MG6 cell Concentration:10 μM Incubation Time:0, 6, 12, 24 hours Result:Significantly inhibited pro-inflammatory cytokine Il-1β, Tnf-α, Il-6, and Cox-2 mRNA level.

Geranylgeraniol (725 mg/kg/d; p.o.; 90 d) is not toxicologically significant with a dose below 725 mg/kg/d in rats.Geranylgeraniol (483 mg/kg/d; p.o.; 10 d) suppresses lipopolysaccharide-induced inflammation via inhibition of nuclear factor-κB activation in rats. Animal Model:Han Wistar rats (169-192 g for male; 116-152 g for female)Dosage:0, 725, 1450, and 2900 mg/kg Administration:Oral gavage; once daily; 90 days Result:Showed the lowest observed adverse effect level (LOAEL) for local effects and the no observed adverse effect level (NOAEL) for systemic effects as 725 mg/kg/d.Reduced body weights by 12.9 and 21.6% in the intermediate- and high-dose group males, respectively, compared to controls.Animal Model:Wistar rats (male, 8-week-old, 130-150 g) Dosage:0, 48.3, 483, 4830 mg/kg Administration:Oral gavage; once daily; 10 days; with or not LPS challenge (i.p.; 0.5 mg/kg)Result:Suppressed LPS-induced inflammatory cytokines and mRNA expression of LPS-induced inflammatory genes in liver with doses of 483 mg/kg and 4830 mg/kg.Suppressed protein levels of IRAK1, TRAF6, and TAK1, originating from transcriptional down-regulation with doses of 483 mg/kg and 4830 mg/kg.

Tetraprenol | FT0626663 | CJ24095

Apoptosis

Apoptosis

Apoptosis

——

——

24034-73-9

290.491

C20H34O

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (344.26 mM)

CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CO

——

(-20℃)

With Ice Pack

≥ 2 years